Current status of cancer proteogenomics: a brief introduction

E. Hattori, T. Kondo
{"title":"Current status of cancer proteogenomics: a brief introduction","authors":"E. Hattori, T. Kondo","doi":"10.2198/jelectroph.63.33","DOIUrl":null,"url":null,"abstract":"Proteogenomics is a novel approach to understand the molecular backgrounds of diseases. In cancer research, proteomic studies have been conducted without using the genome data of individual samples. For example, a common public database has always been used to identify proteins by mass spectrometry. However, tumor genomes, even tumors of the same type of cancer, can differ considerably, and such differences affect the response to treatments. Thus, genomic backgrounds should be considered when identifying proteins by mass spectrometry. In cancer proteogenomics, a virtual proteome database is generated using the genome data of identical samples for the mass spectrometric identification of proteins reflecting genetic mutations, which are not common and not cited in the commonly used databases. Such proteins are candidate biomarkers and therapeutic targets. Although previous studies have reported software capable of translating genomic data to proteomic data, a standard protocol has not been established. In addition, the utility of proteogenomics has also not been established, and it is not self-evident that proteins with mutations unique to certain groups can be exploited for innovative treatments or to provide clues for the resolution of biological problems in cancers. Collaborative efforts by cancer researchers and specialists in mass spectrometry and bioinformatics are required for fruitful advancements.","PeriodicalId":15059,"journal":{"name":"Journal of capillary electrophoresis","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of capillary electrophoresis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2198/jelectroph.63.33","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Proteogenomics is a novel approach to understand the molecular backgrounds of diseases. In cancer research, proteomic studies have been conducted without using the genome data of individual samples. For example, a common public database has always been used to identify proteins by mass spectrometry. However, tumor genomes, even tumors of the same type of cancer, can differ considerably, and such differences affect the response to treatments. Thus, genomic backgrounds should be considered when identifying proteins by mass spectrometry. In cancer proteogenomics, a virtual proteome database is generated using the genome data of identical samples for the mass spectrometric identification of proteins reflecting genetic mutations, which are not common and not cited in the commonly used databases. Such proteins are candidate biomarkers and therapeutic targets. Although previous studies have reported software capable of translating genomic data to proteomic data, a standard protocol has not been established. In addition, the utility of proteogenomics has also not been established, and it is not self-evident that proteins with mutations unique to certain groups can be exploited for innovative treatments or to provide clues for the resolution of biological problems in cancers. Collaborative efforts by cancer researchers and specialists in mass spectrometry and bioinformatics are required for fruitful advancements.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
癌症蛋白质基因组学研究现状简介
蛋白质基因组学是一种了解疾病分子背景的新方法。在癌症研究中,蛋白质组学研究在不使用个体样本的基因组数据的情况下进行。例如,一个通用的公共数据库一直用于通过质谱法鉴定蛋白质。然而,肿瘤基因组,即使是同一类型的肿瘤,也可能存在很大差异,这种差异会影响对治疗的反应。因此,在质谱鉴定蛋白质时应考虑基因组背景。在癌症蛋白质基因组学中,利用相同样品的基因组数据生成虚拟蛋白质组数据库,用于质谱鉴定反映基因突变的蛋白质,这些蛋白质在常用数据库中不常见且未被引用。这些蛋白是候选的生物标志物和治疗靶点。尽管先前的研究已经报道了能够将基因组数据转换为蛋白质组学数据的软件,但尚未建立标准协议。此外,蛋白质基因组学的效用也尚未建立,并且某些群体特有的突变蛋白质可以用于创新治疗或为解决癌症的生物学问题提供线索,这并非不言而喻。癌症研究人员和质谱和生物信息学专家的合作努力是卓有成效的进步所必需的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Electrophoretic extraction of protein complexes after separation and detection by a combined method of non-denaturing two-dimensional electrophoresis and reversible staining Use of Escherichia coli expression system for analyzing kinase motifs Proteomic analysis of spheroids of rhabdomyosarcoma cells cultured with decellularized muscle extracts Drug screening and kinase activity profiling of a novel patient-derived cell line of clear cell ovarian carcinoma Proteogenomic approach to drug targets in osteosarcomas with different original sites
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1